The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX)
- PMID: 31351659
- DOI: 10.1016/j.jsxm.2019.05.016
The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX)
Abstract
Introduction: Cligosiban is an orally administered oxytocin receptor antagonist being developed to treat premature ejaculation (PE).
Aim: To determine the safety and efficacy of cligosiban capsules (dose range 400-800 mg) to improve intravaginal ejaculation latency time (IELT) and patient-reported outcomes in men with severe lifelong PE.
Methods: Patients recorded details of at least 4 sexual intercourse events during a 4-week run-in period, after which they underwent baseline assessments. Patients were eligible for the study if they rated their control of ejaculation as poor/very poor and their stopwatch-assessed IELT was ≤1 minute in ≥75% of intercourse attempts. Eligible patients were randomized to an 8-week treatment period with double-blind cligosiban or placebo (to be taken 1 to 6 hours prior to sexual activity). The starting dose was 400 mg (not more than 1 dose per day) which could be increased to 800 mg after 2 and/or 4 weeks of treatment. Assessments were conducted at 2, 4, and 8 weeks.
Main outcome measure: Efficacy measures were comprised of IELT, self-rating of ejaculation control and ejaculation-related distress (recorded in an electronic diary after each intercourse attempt), premature ejaculation profile, and the Clinical Global Impression of Change.
Results: The mean ratio of fold change from baseline in IELT to the last 4 weeks of treatment (cligosiban/placebo) was 1.9 compared to a baseline of 1.0 (P = .0079). The mean increase in IELT from baseline to the last 4 weeks of treatment was 61.0 seconds for cligosiban, which was significantly different from (and 3.6-fold greater than) the mean increase of 16.4 seconds for placebo (P = .0086). Statistically significant improvements in ejaculation control and ejaculation-related personal distress scores were also observed for cligosiban compared to little or no change with placebo. Cligosiban was generally well tolerated, with no serious or severe adverse events or other safety parameters.
Clinical implications: This proof-of-concept study demonstrated the potential for cligosiban, an oxytocin antagonist, to successfully treat symptoms of severe lifelong PE.
Strengths and limitations: This was a Phase II, randomized, double-blind, placebo-controlled study that was adequately powered to detect a clinically meaningful difference in change in IELT between cligosiban and placebo. Larger studies will be needed to confirm these findings, determine the optimal dose of cligosiban and assess efficacy in men with acquired PE.
Conclusions: Cligosiban was well tolerated, and resulted in significant benefits in both objective and subjective measures of ejaculatory control in men with lifelong PE and therefore offers significant potential as an on-demand, orally administered agent for the treatment of PE. McMahon C, Althof S, Rosen R, et al. The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX). J Sex Med 2019; 16:1178-1187.
Trial registration: ClinicalTrials.gov NCT02232425.
Keywords: Cligosiban; Efficacy; Oxytocin receptor antagonist; Premature ejaculation.
Copyright © 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.
Comment in
-
Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?J Sex Med. 2019 Nov;16(11):1863-1864. doi: 10.1016/j.jsxm.2019.08.010. Epub 2019 Sep 18. J Sex Med. 2019. PMID: 31542352 No abstract available.
-
Response to Letter to the Editor Regarding "Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?".J Sex Med. 2019 Nov;16(11):1864-1865. doi: 10.1016/j.jsxm.2019.08.023. J Sex Med. 2019. PMID: 31672288 No abstract available.
Similar articles
-
The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX).J Sex Med. 2019 Aug;16(8):1188-1198. doi: 10.1016/j.jsxm.2019.05.015. J Sex Med. 2019. PMID: 31351660 Clinical Trial.
-
Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study.J Sex Med. 2013 Oct;10(10):2506-17. doi: 10.1111/jsm.12272. Epub 2013 Aug 12. J Sex Med. 2013. PMID: 23937679 Clinical Trial.
-
Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.J Sex Med. 2018 Nov;15(11):1547-1557. doi: 10.1016/j.jsxm.2018.09.006. Epub 2018 Oct 16. J Sex Med. 2018. PMID: 30341006 Clinical Trial.
-
An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second international society for sexual medicine ad hoc committee for the definition of premature ejaculation.Sex Med. 2014 Jun;2(2):41-59. doi: 10.1002/sm2.27. Sex Med. 2014. PMID: 25356301 Free PMC article. Review.
-
An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation.J Sex Med. 2014 Jun;11(6):1423-41. doi: 10.1111/jsm.12524. Epub 2014 May 22. J Sex Med. 2014. PMID: 24848805 Review.
Cited by
-
Current and emerging treatment options for premature ejaculation.Nat Rev Urol. 2022 Nov;19(11):659-680. doi: 10.1038/s41585-022-00639-5. Epub 2022 Aug 25. Nat Rev Urol. 2022. PMID: 36008555 Review.
-
Oxytocin, Erectile Function and Sexual Behavior: Last Discoveries and Possible Advances.Int J Mol Sci. 2021 Sep 26;22(19):10376. doi: 10.3390/ijms221910376. Int J Mol Sci. 2021. PMID: 34638719 Free PMC article. Review.
-
Oxytocin receptor is a promising therapeutic target of malignant mesothelioma.Cancer Sci. 2021 Sep;112(9):3520-3532. doi: 10.1111/cas.15025. Epub 2021 Jul 4. Cancer Sci. 2021. PMID: 34115916 Free PMC article.
-
Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate.Sci Rep. 2021 Mar 18;11(1):6352. doi: 10.1038/s41598-021-85439-4. Sci Rep. 2021. PMID: 33737570 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources